Overview
- Pfizer said its experimental drug sigvotatug vedotin did not significantly improve overall survival versus standard chemotherapy docetaxel in patients with advanced, inoperable non‑small cell lung cancer.
- The company described the result as one study in a broader program and confirmed it will continue development, highlighting an ongoing late‑stage trial testing the drug together with Merck’s Keytruda in first‑line patients.
- Sigvotatug vedotin is a directed antibody‑drug conjugate that delivers a toxin to tumor cells by targeting integrin beta‑6, a protein reported to be expressed in roughly 90% of non‑small cell lung cancers.
- Investor expectations had been tempered after Pfizer narrowed the pivotal study to focus on overall survival, and the trial news pushed Pfizer shares down about 1.5% in late trading.
- The outcome leaves Pfizer dependent on combination strategies, earlier‑line testing and biomarker selection to salvage the asset, with direct consequences for patients who currently have limited non‑surgical treatment options.